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nterleukin-32 (IL-32), which was 
previously called natural killer 
cell transcript 4, has recently been 
recognized as a proinﬂ  ammatory 
cytokine (see Glossary) [1]. The main 
sources of IL-32 are natural killer 
cells, T cells, epithelial cells, and 
blood monocytes. Four transcripts of 
IL-32 are known at present. IL-32 has 
emerged as an important player in 
innate and adaptive immune responses, 
and information is emerging on 
synergism between IL-32 and other 
well-characterized players in innate 
immunity.
    The innate immune response 
depends on the recognition of 
pathogen-associated molecular 
patterns by families of pathogen 
recognition receptors. The best 
characterized among these are the 
Toll-like receptor (TLR) [2] and the 
nucleotide-binding oligomerization 
domain (NOD) [3] families of 
proteins. Recent studies have shown 
that IL-32 synergizes with NOD1 and 
NOD2 ligands to stimulate IL-1β and 
IL-6 release in a caspase-1-dependent 
manner [4]. These ﬁ  ndings are 
of potential clinical importance 
in settings where NOD2 plays a 
protective role, such as in Crohn’s 
disease, where NOD2-dependent 
production of defensins and cytokines 
contributes to antimicrobial defense 
in the gut. These ﬁ  ndings are 
also likely to be of signiﬁ  cance in 
tuberculosis. Individuals homozygous 
for the 3020ins C NOD2 mutation 
show a defective cytokine response to 
  Mycobacterium tuberculosis   [5]. It is in 
this context that the study reported by 
Netea et al. in   PLoS Medicine  , in which 
the authors explored the regulation 
of IL-32 production by primary cells 
of the immune system, is of potential 
importance [6].
    Stimulation of IL-32 by 
Mycobacteria
    Netea et al. explored the role of IL-
32 in the context of   M. tuberculosis   
infection. In their study, freshly 
obtained human peripheral blood 
mononuclear cells (PBMCs) were 
stimulated with different TLR agonists, 
and gene expression and synthesis of 
IL-32 was determined. The authors 
showed that   M. tuberculosis   could elicit 
IL-32 release from PBMCs as well as 
from purifed monocyte populations. 
This is the ﬁ  rst documented instance 
of a probable role of IL-32 in the 
immune response elicited by an 
intracellular pathogen. The authors 
also found that other heat-killed 
organisms, such as   Staphylococcus 
aureus  ,   Candida albicans  , or   Aspergillus 
fumigatus  , do not stimulate IL-
32 production, although these 
organisms are potent inducers of the 
proinﬂ  ammatory cytokines IL-6 and 
TNF-α.
    This study showed that the 
expression of the genes of isoforms 
α and γ of IL-32 is stimulated by   M. 
tuberculosis  , whereas the gene for the 
β isoform is constitutively expressed 
(i.e., always expressed, even without 
a stimulus). The authors provide 
evidence in favor of a role of IFN-γ in 
the induction of IL-32 synthesis. They 
went on to show that   M. tuberculosis   
elicits caspase-1-dependent cleavage 
of the precursor of IL-18, its release, 
and IL-18-dependent production of 
IFN-γ, which could be blocked by IL-
18 blocking peptide. The authors also 
claim that TNF-α release from PBMCs 
challenged with   M. tuberculosis   occurs in 
an IL-32-independent manner.
  Strengths  and  Weaknesses 
of the Study
    The crucial role of IFN-γ in 
antimycobacterial immunity has 
been shown in patients with defects 
in the IFN-γ receptor [7]. Netea and 
colleagues’ ﬁ  ndings raise important 
questions regarding (a) how IL-32 
levels vary in patients with defects in 
IFN-γ receptors who are susceptible 
to tuberculosis and (b) how these 
variations may impact the course of 
the infection. One of the deﬁ  ciencies 
of their study stems from the fact 
that the role of IL-32 in controlling 
  M. tuberculosis  -dependent cytokine 
networks has not been investigated 
directly by neutralizing or blocking 
IL-32. Rather, the authors’ inferences 
have been drawn indirectly through 
blocking IFN-γ and IL-18 signaling. 
PR3 has recently been identiﬁ  ed as 
an IL-32 binding protein [8], and 
therefore researchers can now explore 
the effect of neutralizing IL-32 using 
enzymatically inactive PR3 or PR3-
derived peptides.
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  IL-32 has emerged 
    as an important player 
in innate and adaptive 
immune responses. 
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    In addition, the present report fails 
to address how the synthesis of the 
different isoforms of the IL-32 protein 
is regulated, which will require future 
exploration. IL-32 has been reported to 
induce the pro-inﬂ  ammatory cytokines 
TNF-α and IL-1β from murine 
peritoneal macrophages, as well as from 
phorbol ester-differentiated human 
THP-1 cells [1]. Netea et al. show that 
IL-32 production is not associated 
with TNF-α induction. This raises the 
question whether the differences in 
TNF-α induction are attributable to 
intrinsic differences in behavior of 
monocytic cells in comparison with 
differentiated macrophages.
    The ﬁ  ndings reported in this study 
raise interesting questions and open 
avenues for further exploration. 
One question is whether external 
stimuli such as IFN-γ regulate IL-32 
at both the transcriptional as well 
as the translational level. The likely 
roles of the 5′- and 3′-untranslated 
regions (UTRs) of the IL-32 mRNA in 
regulating IL-32 production need to be 
deciphered. IL-32 production has been 
observed to be TLR independent but 
IFN-γ dependent [1]. MyD88, a classical 
TLR adapter protein [2] central to 
TLR signaling, has recently been shown 
to signal through the IFN-γ receptor 
[9] through a non-Toll-IL-1R domain. 
MyD88 stabilizes mRNA through 
classical AU-rich elements found in 
the 3′ UTRs of many mRNAs. Does 
MyD88 have any role in relation to the 
production of IL-32? This question is 
particularly important in view of the 
report showing fatal   M. tuberculosis   
infection in mice in the absence of 
MyD88 [10]. In general, interactions 
between 5′ and 3′ UTRs resulting 
in the formation of an RNA loop 
increase translational efﬁ  ciency [11], 
and RNA-binding proteins act at the 
level of enhancing or repressing these 
interactions to control translation. 
The control processes that regulate 
translation of IL-32 are additional areas 
of future exploration.
  Clinical  Implications
    For the clinician, IL-32 emerges as 
yet another cytokine whose role in 
the course of tuberculosis and related 
infections deserves evaluation. The 
cellular receptor (or interacting 
partner) for IL-32 needs to be 
identiﬁ  ed in antigen-presenting cells, 
which are of particular relevance to 
tuberculosis. IL-32 contributes to 
the synovitis of rheumatoid arthritis, 
and the inﬂ  ammation of rheumatoid 
arthritis correlates with IL-32 gene 
expression [12]. While considering 
intervention at the level of IL-32 
for autoimmune disorders, its role 
in mounting an effective immune 
response against invading pathogens 
also needs to be considered. It 
would be pertinent to bear in mind 
that neutralization of IL-32 could 
render patients more susceptible to 
tuberculosis. The risk of tuberculosis 
in patients on anti-TNF-α therapy has 
already been documented [13].
    The most important question raised 
by these studies is why   M. tuberculosis   
induces IL-32 whereas other organisms 
that are known inducers of IFN-γ 
do not. The identiﬁ  cation of likely 
additional IL-32 regulating pathways 
triggered uniquely by mycobacteria 
deserves immediate attention.   
 Glossary
   Cytokines:  Broad group of signaling 
proteins that are in general produced by 
immune cells after cell activation and act 
as autocrine or paracrine regulators of 
the immune response.
   Natural  killer  cells:  Large, granular, 
bone-marrow-derived lymphocytes of 
the innate immune system that release 
cytolytic molecules to kill infected cells 
and tumor cells.
   PAMPS:  Speciﬁ  c conserved structures 
of pathogens recognized by pattern 
recognition receptors on macrophages 
and dendritic cells.
   Toll-like  receptor:  Germline-encoded 
pattern recognition receptors that 
recognize conserved molecular patterns 
shared by microorganisms.
   NOD  families  of  proteins:  A family 
of cytoplasmic proteins that contain a 
nucleotide-binding site and a leucine-
rich repeat and function as cytosolic 
sensors involved in innate recognition 
of microorganisms and regulation of 
inﬂ  ammatory responses.
   Interleukins:  Secreted regulatory 
proteins produced by immune cells 
such as monocytes and lymphocytes in 
response to stimuli that help the immune 
system ﬁ  ght infection and diseases such 
as cancer.
   Caspase-1  dependent:  Refers to the 
thiol protease caspase-1-mediated 
proteolytic processing of the precursor 
form of IL-18 to the mature, active form 
of the cytokine.
   Defensins:  Cationic, cysteine-rich 
peptides found in the cytoplasmic 
granules of neutrophils and macrophages 
possessing broad antimicrobial activity 
against bacteria, fungi, and enveloped 
viruses.
   PR3:  A granule serine protease present 
in neutrophils and monocytes capable 
of processing a variety of biological 
substrates.
   MyD88:  An adapter molecule that binds 
to the intracellular domains of TLRs and 
recruits a number of molecules to the TLR 
complexes to trigger signaling. 
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